The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

@article{Birkmayer2005ThePO,
  title={The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil},
  author={Walther Birkmayer and Peter Franz Riederer and Moussa B. H. Youdim and W. Linauer},
  journal={Journal of Neural Transmission},
  year={2005},
  volume={36},
  pages={303-326}
}
The potentiation of the ami akinetic effect after L-Dopa treatment by an inhibitor of monoamine oxidase (MAO) “B”, Deprenil, has been demonstrated in parkinsonian patients with or without previous L-Dopa therapy. Application of the drug has been performed orally, intravenously and intramuscularly. Excellent kinetic effects resulted when combined with Madopar. The combined treatment with L-Dopa was highly effective when applicated i.v. or i.m. Deprenil is an inhibitor of MAO-B and is… 
View on Springer
ncbi.nlm.nih.gov
149 Citations
Highly Influential Citations
4
Background Citations
52
Methods Citations
7
Results Citations
4

149 Citations

The clinical and biochemical investigation of L-deprenyl in Parkinson's disease with special reference to the “on-off” effect
TLDR
The effect of L-deprenyl in combination with L-Dopa was studied in 22 Parkinsonian patients, with various forms of “on-off” phenomena, and the results were very encouraging with regard to amelioration of ” on-off effect”.
On the mode of action of L-deprenyl in the human central nervous system
TLDR
In vitro studies demonstrated that (-)deprenyl in comparison to d, l-tranylcypromine, clorgyline and harmaline is by far the most potent inhibitor of human brain MAO, and long-term treatment with more than 1 mg/10 kg body weight could result in an accumulation of (-)DeprenylIn the brain.
The possible mechanisms of action of (-)deprenyl in Parkinson's disease
  • J. Knoll
  • Biology, Chemistry
    Journal of Neural Transmission
  • 2005
TLDR
The advantage of the combination of levodopa and (-)deprenyl in the treatment of Parkinson's disease was summarized as follows.
The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man
TLDR
The effect of (-)-deprenyl, a rapidly acting selective monoamine oxidase (MAO) B inhibitor, on the sleep and mood of six healthy young male adults was investigated and the only effect of the drug on mood was to decrease the level of alertness prior to sleep.
Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
TLDR
Results are interpreted as indicating l-deprenyl's ability to prevent or retard the degeneration of striatal dopaminergic neurons, the first anti-Parkinson drug having such a property.
Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition
TLDR
Because of their selective action on the specific forms ofMAO, which results in selective elevation of brain noradrenaline and serotonin on the one hand and dopamine and phenylethylamine on the other, it is hoped that these drugs will be able to elucidate the functional roles of MAO-A and B subtypes with regards to dopamine metabolism in the human brain.
L-deprenyl treatment of on-off phenomena in Parkinson's disease
TLDR
It was concluded that L-deprenyl seems to provide a valuable adjuvant to levodopa in patients with on-off disabilities.
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
TLDR
The clinical potential of MAO inhibitors together with detailed knowledge of the enzyme's binding site structure should lead to future developments with these drugs.
MAO-inhibitors in Parkinson's Disease
TLDR
In general, the clinical use of MAO-I nowadays is underestimated and there should be more efforts to evaluate their clinical potency as antidepressants and antidementive drugs in addition to the final proof of their disease-modifying potential.
Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior
TLDR
The effect of enzyme-inhibiting adjuvants on L-DOPA + benserazide-induced contralateral turning in unilateral 6-hydroxydopamine-lesioned rats was studied and a further potentiation of turning behavior was observed after the combined administration of both the MAO-A and COMT inhibitor.
...
...

References

SHOWING 1-10 OF 73 REFERENCES
L-dopa level in plasma, primary condition for the kinetic effect
TLDR
For producing kinetic effects a sufficient availability of L-Dopa in plasma is necessary and a sufficient utilization in the brain has to be and in cases of akinetic crisis a combined infusion of L ofopa plus amantadine-sulfate is a vital indication.
Monoamine oxidase. Its inhibition.
TLDR
There is now a revival of interest in the functional role of MAO in the central nervous system and drugs that inhibit or stimulate its activity "specifically", and the advent of new drugs with "selective" inhibition of enzyme forms.
Effect of Pretreatment with Oestradiol, Progesterone and DOPA on Monoamine Oxidase Activity in the Rat
TLDR
To investigate the possibility that physiologically occurring cyclical increases in MAO activity might represent an adaptive response to increased availability of substrate, it is attempted to evaluate this possibility indirectly by treating rats before enzyme assay with DOPA which leads to increased tissue levels of the MAO substrate, dopamine.
Biological Sciences: Human Brain Monoamine Oxidase: Multiple Forms and Selective Inhibitors
TLDR
An explanation might be sought in terms of differential inhibitory capacity of these drugs on the four molecular variants of MAO in the human brain on the basis of differing ability of the MAO inhibitors to prevent amine re-uptake.
“On‐off” phenomenon with levodopa therapy in parkinsonism
  • S. Fahn
  • Psychology, Medicine
    Neurology
  • 1974
TLDR
Serial half-hourly measurements of plasma levels of dopa, 3-O-methyldopa, and homovanillic acid showed partial concordance between clinical fluctuation and plasma dopa levels in patients receiving levodopa alone or in combination with carbidopa.
Dopamine and basal ganglia diseases.
  • A. Barbeau
  • Medicine, Biology
    Archives of neurology
  • 1961
TLDR
Recent developments in biochemical changes in mental disease, especially alterations in catechol-amine and serotonin metabolism, are becoming increasingly important, and it may be that the present findings will give some recent developments in this field the attention of neurologists.
Alterations in the Pattern of Amine Excretion in Man Produced by a Monoamine Oxidase Inhibitor
TLDR
The finding that the excretions of norepinephrine, epinephrine, 3,4-dihydroxyphenylethylamine, and possible serotonin are not appreciably affected are consistent with previous reports of the existence of alternative metabolic routes.
Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets.
TLDR
Increased enzyme activity related to aging and sex may be a biologic factor that, in association with Psychological and social stresses, predisposes certain individuals to the development of depression.
The daily rhythm of HVA, VMA, (VA) and 5-HIAA in depressionsyndrom
TLDR
The daily rhythm of HVA, VMA, (VA) and 5-HIAA was studied in 21 depressed patients and was compared to the values of 13 healthy subjects, showing a good connexion to the clinical feature with the morning listlessness.
THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL.
  • A. AntonD. Sayre
  • Biology
    The Journal of pharmacology and experimental therapeutics
  • 1964
In the paper, "The Distribution of Dopamine and Dopa in Various Animals and a Method for Their Determination in Diverse Biological Material" by A. H. Anton and D. F. Sayre (Volume 145, pages 326-336,…
...
...